[Age-related macular degeneration: therapeutic hopes].
Behar-Cohen
Francine
F
Inserm U598, Physiopathologie des maladies oculaires, Innovations thérapeutiques, Centre de Recherches Biomédicales des Cordeliers, 75270 Paris Cedex 06, France. behar@idf.inserm.fr
Sennlaub
Florian
F
Berdugo
Marianne
M
D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000494:pharmacology / Q000627:therapeutic use; D000068258:Bevacizumab; D004311:Double-Blind Method; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab